SHENZHEN, Sept 23, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 22 September 2025, the Group through its subsidiaries entered into two separate exclusive Collaboration Agreements (the “Agreements”) with Chongqing Genrix Biopharmaceutical Co., Ltd. (“Genrix Bio”) for two Class 1 therapeutic biological products, Vecantoxatug Injection (GR2001, “Vecantoxatug”) indicated for passive immunization against tetanus and Silevimig Injection (GR1801, “Silevimig”) indicated for passive immunization following suspected rabies virus exposure, respectively. In accordance with the Agreements, the Group has obtained exclusive commercialization rights for these two products in mainland China and exclusive licensing rights for the rest of the Asia-Pacific region, the Middle East and North Africa. The collaboration terms respectively extend until ten years after these two products receive their marketing approvals in Mainland China (the “Initial Term for each Product”). Unless terminated or dissolved under the terms set forth in the Agreements, the Agreements will automatically renew for successive ten-year periods upon expiration of the Initial Term for each Product.Vecantoxatug is a passive immunization agent with an excellent safety profile, which delivers superior protection compared with human tetanus immunoglobulin (HTIG), providing rapid and durable immune defense for patients. Its Phase III clinical trial for passive immunization against tetanus successfully met the primary efficacy endpoint. In May 2024, Vecantoxatug was designated Breakthrough Therapy by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). On 22 May 2025, its New Drug Application (NDA) was formally accepted by the CDE.Silevimig is the world’s first recombinant, fully human bispecific antibody against rabies virus (RABV) targeting epitope I and/or epitope III of the rabies virus glycoprotein, developed in accordance with the World Health Organization (WHO) recommended “cocktail” therapeutic option targeting distinct antigenic sites. It can be manufactured at scale with standardized, and also demonstrates broad neutralization, low immunogenicity, minimal interference with vaccine-induced active immunity, and controlled production cost. On 14 January 2025, its NDA for use in adults requiring passive immunization following suspected rabies virus exposure was formally accepted by CDE. In addition, in July 2025, the NMPA approved the clinical trial application for Silevimig in children and adolescents aged 2 to <18 years requiring passive immunization following suspected rabies virus exposure. This Phase III clinical trial is currently in progress.CMS has always been committed to deploying innovative products with clinical value and differentiated advantages. The market for tetanus and rabies passive immunization remains substantial, yet existing passive immunization products are constrained by safety and accessibility concerns. If approved, Vecantoxatug and Silevimig will provide new preventive and therapeutic options of passive immunization for patients following tetanus and rabies exposure. Additionally, they will synergize with the Group’s existing products in expert networks and market resources, bringing benefit to patients.More information about Vecantoxatug and TetanusVecantoxatug is a recombinant humanized monoclonal antibody against tetanus neurotoxin (TeNT), which is self-developed by Genrix Bio. Vecantoxatug binds to the fragment C domain of the TeNT heavy chain (TeNT-Hc). TeNT is an about 150 kDa single-chain protein that undergoes post-translational modification to form an active toxin composed of heavy and light chains. By specifically binding TeNT-Hc, Vecantoxatug effectively blocks toxin entry into neurons, providing passive immunization. The patent for Vecantoxatug has been granted in China.Tetanus is an acute and specifical infection caused by Clostridium tetani (C. tetani) entering the body through wounds. It affects individuals across all age groups and, in the absence of medical intervention, is almost universally fatal-particularly among infants and the elderly. Even with active treatment, global mortality remains as high as 30-50%, with an estimated 500,000 to 1,000,000 cases reported annually worldwide[1].C. tetani is ubiquitous in soil and the environment, and is also present in the intestines of mammals. As the pathogen invades through skin or mucosal injuries, causing the acute and specifical infection, prevention remains the most effective strategy. Currently available passive immunization agents, commonly known as tetanus shot, - tetanus antitoxin (TAT), equine-derived tetanus immunoglobulin (F(ab’)2), and human tetanus immunoglobulin (HTIG) - face notable limitations in safety and accessibility[2], including risks of allergic reactions, potential infectious pathogen transmission, and limited availability. Consequently, there remains a pressing clinical need for new preventive and therapeutic options. Vecantoxatug is able to provide greater protection than HTIG, while demonstrating excellent safety, tolerability, and low immunogenicity. With enhanced controllability and accessibility, Vecantoxatug has the potential to offer patients an advanced preventive and therapeutic option.More information about Silevimig and RabiesSilevimig is a recombinant, fully human bispecific antibody against rabies virus, which is self-developed by Genrix Bio. It targets the viral envelope glycoprotein (G protein) of RABV and blocks its interaction with host receptors by binding to epitopes I and/or III. Through this mechanism, Silevimig prevents RABV from invading neural tissue prior to the establishment of full protection by active rabies vaccination, thereby helping to prevent rabies infection. Silevimig’s molecular design is consistent with the recommendations of the WHO for anti-RABV antibody development, which emphasize the use of “cocktail” combinations of monoclonal antibodies targeting distinct antigenic sites to ensure broad effectiveness across different viral strains and genotypes. The patent for Silevimig has been granted in China.In a Phase III clinical trial for post-exposure passive immunization in adults, Silevimig met its primary efficacy endpoint, demonstrating non-inferior protective efficacy compared with human rabies immunoglobulin (HRIG), the currently most used passive immunization product in China. The study confirmed that Silevimig provides immediate protection during the early stages of rabies virus exposure without compromising the active immune response induced by vaccination.Rabies is an acute zoonotic disease caused by RABV, clinically characterized by hydrophobia, aerophobia, pharyngeal muscle spasms, and progressive paralysis[3]. With a case-fatality rate approaching 100%, it is one of the deadliest diseases worldwide. At present, there is no proven treatment for rabies once clinical symptoms appear. Standardized Post-Exposure Prophylaxis (PEP), comprising wound care, vaccination, and passive immunization administered as needed, remains the most effective rabies prevention strategy[4]. As vaccine-induced antibodies require 1–2 weeks after the first dose of vaccine injection, to reach protective levels (≥0.5 IU/mL), passive immunization provides immediate coverage during this high-risk window[3]. According to the the National Regulation for the Rabies Exposure Prophylaxis (2023 Edition), patients with Category III exposure and those with severe immunodeficiency and Category II exposure should receive passive immunization at the same time as the first dose of rabies vaccine[5]. In China, more than 40 million people are exposed to rabies annually, of whom approximately 40% (16 million) fall under Category III exposure[3]. However, due to factors such as limited awareness, high cost, and restricted accessibility, only about 15% of Category III cases receive passive immunization[3].Currently approved passive immunization options in China include human rabies immunoglobulin (HRIG) and equine rabies antiserum (ERA), both of which provide immediate protection by preventing viral entry into neural tissue. HRIG must be sourced from repeatedly immunized healthy donors, making it difficult and costly to obtain. And it is associated with potential risks of blood-borne infections (e.g., HIV, hepatitis B, hepatitis C). ERA, being a heterologous protein, is prone to adverse reactions such as serum sickness and anaphylactic shock[3]. Beyond HRIG and ERA, only two rabies antibody products have been approved in China to date. Silevimig is the world’s first recombinant, fully human bispecific antibody for passive immunization against rabies, which is consistent with the WHO recommended “cocktail” approach. Its approval is expected to provide patients with broad and robust protection.About GENRIX BIOGenrix Bio (Stock Code: 688443), founded in 2015, is an innovative biopharmaceutical company driven by advanced antibody drug discovery technology to address critical clinical needs. Genrix Bio is committed to the development of monoclonal and bispecific antibodies for autoimmune diseases, infectious diseases, and oncology. Its capabilities span across antibody molecular discovery, process development and quality research, clinical trials, and large-scale commercialization. Learn more about Genrix Bio and its products at https://www.genrixbio.com/About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development.Reference:1. China Trauma Rescue and Treatment Association. Peking University Trauma Medicine Center. Chinese expert consensus on tetanus immunization[J]. Chinese Journal of Surgery,2018,56(3):161-167. DOI: 10.3760/cma.j.issn.0529-5815.2018.03.0012. Members of the Emergency Surgery Committee of Chinese College of Emergency Physicians, Members of the Emergency Medicine Committee of the People's Liberation Army, Beijing Society for Emergency Medicine, et al. Expert consensus on prophylaxis, diagnosis and management of tetanus among adults[J]. Journal of Clinical Emergency, 2018, 19(12):801-811. DOI: 10.13201/j.issn.1009-5918.2018.12.0013. Chinese Center for Disease Control and Prevention. Technical Guidelines for Human Rabies Prevention and Control (2016). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525420231910.pdf4. Yin Wenwu, Wang Chuanlin, et al. Expert consensus on rabies exposure prophylaxis[J]. Chinese Journal of Preventive Medicine, 2019,53(7):668-679. DOI:10.3760/cma.j.issn.0253-9624.2019.07.0045. Chinese Center for Disease Control and Prevention. The National Regulation for the Rabies Exposure Prophylaxis (2023 Edition). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525421817465.pdfCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Sep 23, 2025 - (ACN Newswire via SeaPRwire.com) – On September 16th, the "Industrial Intelligent Water Saving and Efficiency Promotion Event & GreenTech WateRobot AI Agent 1.0 Ecosystem Launch", hosted by the China Industrial Energy Conservation and Cleaner Production Association, GreenTech Environment Co., Ltd., and Beijing Zhenghe Island Information Technology Co., Ltd., was successfully convened in Beijing.Centered on the theme "AI for Water Freedom", the event brought together nearly 400 industry experts, research institutions, universities, environmental protection enterprises, and financial institutions to witness the launch of the WateRobot AI Agent and explore the new developments in water savings and efficiency brought by AI agents to the industry.(Launch event scene)Wang Xiaokang, President of the China Industrial Energy Conservation and Cleaner Production Association, attended and addressed the event, noting that AI empowerment will unlock new possibilities for environmental governance and industrial water conservation, and that the WateRobot AI Agent is an innovative achievement of deep integration between intelligence and water technology. Liu Donghua, Founder and Chief Architect of Zhenghe Island, delivered a speech proposing that the resource utilization of wastewater can find optimal solutions through AI, and that the widespread application and continuous upgrading of the WateRobot AI Agent can inject significant strength into achieving "Water Freedom" for industry, cities, and even the nation.The event invited AI expert Wei Kai, Director of the Artificial Intelligence Research Institute at the China Academy of Information and Communications Technology, to deliver a keynote speech on "Artificial Intelligence+ Policies and Industrial Practices". He pointed out that advancements in large language models have brought new paradigms to the development of AI technology, and the birth of the WateRobot AI Agent represents an important attempt of AI in the field of industrial water treatment.Subsequently, GreenTech officially launched the WateRobot AI Agent. Chairman Zhang Huichun proposed that using AI to replace human management of water plants can achieve industrial assembly line production, modular assembly, unmanned operation, and intelligent operation of water plants, replacing the traditional operational models of conventional engineered water plants. This leads to a 90% reduction in footprint, construction period, and operational staff, as well as a 50% reduction in Life Cycle Cost (LCC), ultimately enabling humanity to obtain Sustainable, Abundant, Reliable, and Affordable High-quality water (SARAH), achieving Water Freedom.(WateRobot AI Agent product interface)Wang Xiaoyu, General Manager of the Digital Technology Business Unit of GreenTech, further elaborated that the WateRobot AI Agent is an AI agent system capable of autonomous operation and completing target tasks. It not only incorporates GreenTech's self-developed process optimization forecasting and decision-making models but also integrates computer vision, auditory, infrared, and other perceptual AI models, as well as domestic large language inference models. Under the Online to Offline closed-loop logic, it directly delivers value to customers——safe, efficient, and optimally cost-operated unmanned water plants. The WateRobot AI Agent has already been applied in newater house water plant scenarios and is expected to expand to other water treatment plants, as well as industrial, agricultural, and municipal facilities, committed to enabling unmanned operation and innovative operational models across various fields.The event featured the unveiling ceremony of the "Artificial Intelligence Innovation Research Center" jointly established by GreenTech and Wuhan University. Zhang Liping, Deputy Director of the Industry-Academia-Research Cooperation Office of the Science and Technology Development Research Institute of Wuhan University, attended the unveiling and delivered a speech. Both parties will conduct in-depth technical research and industry applications focused on unmanned and intelligent operations. A roundtable dialogue on "AI + Industry" with the theme "AI's New Mission: Driving Industrial Restructuring and a Sustainable Future" was also held, where AI experts and various entrepreneurs discussed the application scenarios, value advantages, and future prospects of AI in the industrial field.GreenTech entered into strategic partnerships with the Finance Center for South-South Cooperation, Shanxi Xinzhou Economic Development Zone, CPIC Investment Management (H.K.), Wuhan Easy-Sight Technology Co.,Ltd., Green Technology (Shanghai) Agricultural Technology Co., Ltd., China Construction Eco-Development Co., Ltd., Beijing Boqi Electric Power Technology Co., Ltd., Beijing Zhenghe Island Information Technology Co., Ltd., and China Chemical Enterprise Management Association, among others, to jointly promote the application and promotion of the WateRobot AI Agent in the industry and various sectors domestically and internationally.The launch not only marked the debut of the WaterRobot AI Agent, a "new species" driving intelligent and green transformation in the industry but also envisioned the future of an intelligent water ecosystem——AI for Water Freedom. Through the innovative practices of GreenTech, the mission of "AI assisting industrial water savings and efficiency" has taken a solid step forward. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Sep 23, 2025 - (ACN Newswire via SeaPRwire.com) – Nissin Foods Company Limited (“Nissin Foods”, together with its subsidiaries, the “Group”; Stock code: 1475) is pleased to announce that the Group has entered into contracts for the land use rights of two strategically located parcels of land (the “Land Parcels”) in Zhuhai.Located in the Jinwan District of Zhuhai City, Guangdong Province, the Land Parcels were sold by the Zhuhai Natural Resources Bureau, a government authority responsible for managing land resources. The total consideration for the land is RMB30.68 million, covering a total land area of approximately 58,487 square meters. Nissin Foods plans to invest over RMB240 million to acquire the land, construct new facilities, and install cutting-edge automated production lines. Nissin Foods is committed to providing consumers with high-quality yet affordable food products. Incorporated with advanced automation and labour-saving technologies, the new factory will enhance production capacity and improve efficiency by reducing operational downtime. These initiatives are part of the Group’s commitment to sustainable growth, enabling it to respond flexibly to market changes and keep pace with growing consumer demand for the Group’s premium products. Strategically located in the Greater Bay Area, the new factory will create operational synergies with the current adjacent facilities of the Group.Mr. Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, “Despite global economic uncertainties, Mainland China’s consumer market maintained steady recovery in the first half of 2025, driven by a series of government policies aimed at stimulating consumption and expanding domestic demand. Consequently, the Group’s revenue in Mainland China rose by 9.4% to HK$1,221.9 million in the same period.“This land acquisition aligns perfectly with the company’s strategic goals and supports its ongoing growth. The new land and facilities will help maintain a steady supply of quality products while meeting the anticipated growth in sales. This is expected to inject new momentum into the Group’s operational development and long-term growth prospects, thereby enhancing its overall income and profitability.”For more information, please refer to the announcement on the Hong Kong Stock Exchange website: www1.hkexnews.hk/listedco/listconews/sehk/2025/0911/2025091100394.pdfAbout Nissin Foods Company LimitedNissin Foods Company Limited ("Nissin Foods”, together with its subsidiaries, the “Group”; Stock code: 1475) is a renowned food company in Hong Kong and Mainland China, with a diversified portfolio of well-known and highly popular brands, primarily focusing on the premium instant noodle segment. The Group officially established its presence in Hong Kong in 1984 and is the largest instant noodle company in Hong Kong. The Group primarily manufactures and sells instant noodles, high-quality frozen food products, including frozen dim sum and frozen noodles, and also sells and distributes other food and beverage products, including retort pouches, snacks, mineral water, sauce and vegetable products under its two core corporate brands, namely “NISSIN ” and “DOLL” together with a diversified portfolio of iconic household premium brands. The Group’s five flagship product brands, namely “Cup Noodles”, “Demae Iccho”, “Doll Instant Noodle”, “Doll Dim Sum ” and “Fuku” are also among the most popular choices in their respective food product categories in Hong Kong. In the Mainland China market, the Group has introduced technology innovation through the “ECO Cup” concept and primarily focuses its sales efforts in first-and second-tier cities. In addition, Nissin Foods operates business in other regions including Vietnam, Taiwan, Korea and Australia markets.Nissin Foods is currently a constituent of five Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Composite SmallCap Index, Hang Seng Composite Industry Index - Consumer Staples, Hang Seng SCHK Consumption Index and Hang Seng SCHK Food and Drink Index. Nissin Foods is eligible for trading under Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect. For more information, please visit www.nissingroup.com.hk. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - September 22, 2025) - Gold-copper explorer and hybrid project generator Kincora Copper Limited (ASX: KCC) (TSXV: KCC) (Kincora or the Company) is pleased to announce that it has resecured the full rights of its Mongolian c0pper-gold portfolio following Orbminco Limited's (ASX: OB1) (formerly known as Woomera Mining Limited) withdrawal from the September 2024 Earn-In Agreement as it now focuses on its Australian gold exploration.Assets within the portfolio include:a large Mineral Resource Estimate and Exploration Target reported under the JORC Code by Resilience Mining Mongolia Limited 1 for the West Kasulu prospect, which includes a small portion of one of three extensive, from surface and underexplored copper-gold intrusive complexes (the majority hosted on an existing 30-year mining license);a year-round field camp; and,a proprietary Mongolia wide project generation database.Further details are provided in an Appendix to this release.This development comes at a time of various notable positive developments highlighting the potential of Mongolian's resource sector and the Bronze Fox copper-gold project. These include:Xanadu Mines and its flagship Kharmagtai copper-gold project's recent A$160-million takeover by Bastion Mining Pte. Ltd,Erdene Resource Development's first gold pour at its greenfield Bayan Khundii project,construction of the privately held Tsagaan Suvarga copper-molybdenum project, and,the Oyu Tolgoi copper-gold project being on track to be the world's fourth largest copper mine by 2030.With Kincora now controlling 100% ownership, the Company will move forward to build on existing and new interest in the project.Kincora intends to consider a range of options, including focused self-funded exploration, third party investment and other corporate initiatives. Near term value add activities may include the potential submission for a second mining license at the Bronze Fox project and fresh mining studies relating to the existing oxide resource reflecting recent shifting in commodity prices.Further market updates will be provided following any material development arising to the Company's Mongolian asset portfolio.This announcement has been authorised for release by the Board of Kincora Copper Limited (ARBN 645 457 763)For further information please contact: Kincora Copper Limited Sam Spring, President and Chief Executive Officer sam.spring@kincoracopper.com or +61431 329 345AppendixKincora's Mongolian asset portfolio includes a 100% interest in one of the largest land positions and porphyry complexes in the Southern Gobi copper-gold belt, a region which is one of the world's most rapidly emerging sources of copper supply and infrastructure development.The Company's Mongolian portfolio assets include:Bronze Fox mining license (the eastern license of the Bronze Fox project),Tourmaline Hills exploration license (the western license of the Bronze Fox project),White Pearl field camp (year-round facility), and,one of (if not) the largest project generation databases for Mongolia.In July 2022, the Company announced a maiden Inferred Mineral Resource Estimate (MRE) and updated Exploration Target for the West Kasulu prospect within the Bronze Fox project reported under the JORC code and prepared by Resilience Mining Mongolia Limited 1. Both the MRE and Exploration Target are open in all directions 1.The MRE 1 hosts a from surface oxide component with previous metallurgical analysis and desktop studies supporting the potential for a low capex SX-EW (solvent extraction-electrowinning) development project producing a finished copper cathode product.The majority of the MRE and Exploration Target 1 are situated within the existing Bronze Fox mining licence with the balance being on the adjoining Tourmaline Hills exploration licence (collectively the Bronze Fox project).With Kincora now retaining 100% ownership and optionality around adding value to the asset base, the Company intends to consider a range of options including the potential for a near term submission for a second mining license which would provide mining license coverage across the full project and be a major milestone unlocking the potential for a SX-EW development project. Kincora will consider fresh mining studies relating to the existing oxide resource reflecting recent shifting in commodity prices.The West Kasulu prospect is hosted within a small portion of the much larger mineralised Bronze Fox Intrusive Complex, which is one of three so far identified underexplored, near surface and large porphyry complexes at the wider Bronze Fox project.2024 field season activities undertaken by Orbminco Limited included predominately infill drilling, required to support conversion of the existing Tourmaline Hills exploration license to a mining license, plus one deep diamond drill hole 2. The 2025 field season sampling and mapping activities further confirmed and expanded the potential for a higher-grade extension to the current MRE envelope 1, which remains open 3. More recent geophysical programs comprised of Induced Polarisation (IP) and gravity surveys have also been completed reconfirming existing targets and identified additional targets for further review 4.2025 field sampling and geophysical programs have also been undertaken at the Shuteen North target, which hosts extensive sub-cropping copper mineralisation and multiple intrusive systems 3 4. The Shuteen North target has never been previously drilled and is interpreted to be associated with the Shuteen lithocap, the largest lithocap in the Southern Gobi. The importance of this conceptual geological setting is significant given the lithocap at the Oyu Tolgoi project was an important early-stage exploration marker and the relative size of the Shuteen lithocap relatively to Oyu Tolgoi.The Company continues to defend a tax assessment that was relied upon to complete a merger in 2016, with the Mongolian Supreme Court scheduled to hear this case again in the next month.Please refer to Kincora's website and contact the Company for further details.Footnotes1 The Mineral Resource Estimate (MRE) and Exploration Target have been prepared by independent consultant DG & JG Larsen Consulting Pty Ltd and are reported in accordance with the Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves 2012 (JORC Code) and is not based on Canadian Institute of Mining, Metallurgy and Petroleum (CIM) definitions, and as a result the estimate is not recognized under National Instrument 43-101 of the Canadian Securities Administrators (NI 43-101).The MRE and Exploration Target were commissioned and paid for by Resilience Mining Mongolia Limited, an unrelated party, meeting a condition precedent from a Joint Venture and Acquisition Agreement, and subsequent extension agreement, that was subsequently terminated by Kincora. The MRE and Exploration Target were based on data and geological information supplied by Kincora and Resilience Mining Mongolia Limited.The MRE and Exploration Target were reviewed by Kincora's geological staff under the supervision of Paul Cromie (BSc Hons. M.Sc. Economic Geology, PhD, member of the Australian Institute of Mining and Metallurgy and Society of Economic Geologists), then Exploration Manager Australia, who was the Qualified Persons for the purpose of NI 43-101.In 2022, Kincora retained a 100% interest in the project, data and reports pertaining to the MRE and Exploration Target from Resilience Mining Mongolia Limited (see the July 8, 2022, release "Kincora provides corporate update for Mongolian portfolio" for further details).In September 2024, Kincora executed a definitive agreement with Orbminco Limited's (formerly Woomera Mining Limited) to provide certain rights to the Mongolian project. Under the Earn-In and Joint Venture Agreement with Kincora multiple phases of exploration were undertaken by Orbminco Limited, including:4Q'2024 drilling program: a sixteen hole for 2,516 metre drilling program was completed designed to infill and extend the existing MRE with results that "confirm expansion and higher-grade potential of the West Kasulu resource" 2.1Q'2025 mapping and surface sampling program: the program "validated historic sampling and confirm a high-grade, copper-gold extension structure at the West Kasulu prospect which is open and trends northwest beneath shallow cover". Orbminco noted the "trend remains largely undrilled and that IP and gravity surveys are proposed to facilitate follow up drilling". At the Shuteen North prospect, located 10km southwest of the West Kasulu MRE, "limited previous exploration has recorded extensive sub-cropping copper mineralisation and multiple phase intrusive systems associated with strong mineral alteration, which has been confirmed during the recent mapping" 3.3Q'2025 geophysical program: a "large geophysical survey" included induced polarisation (IP) and gravity survey and followed up the 1Q'2025 mapping and surface sampling program. "Several IP anomalies have been identified to the west of the current resource and at Shuteen North. The results of the completed IP and gravity surveys have reconfirmed the existing targets and identified additional targets for further review" 4.In accordance with the Earn-In and Joint Venture Agreement, Orbminco Limited will within 60 days following the date of effective termination deliver all technical data obtained to Kincora.The Company is not aware of any information otherwise which materially affects the information included in the announcement referred to above and, in the care of the MRE and Exploration Target, all material assumptions and technical parameters underpinning the estimates in that announcement continue to apply.For further details relating to the Mongolian licenses please refer to the Company's website (www.kincoracopper.com) and ASX listing prospectus, including the Mining Associates Technical Export Report (February 25, 2021).References1 Further details and technical disclosures included in the July 26, 2022, Kincora Copper press release "Mineral resource and updated exploration target for Bronze Fox". 2 Further details and technical disclosures included in the January 14, 2025, Orbminco Limited press release "Drilling Results for Bronze Fox Copper-Gold Project". 3 Further details and technical disclosures included in the March 26, 2025, Orbminco Limited press release "High grade copper-gold potential confirmed at Bronze Fox"4 Further details and technical disclosures included in the August 15, 2025, Orbminco Limited press release "Update on Mongolian Operations".Kincora Copper LimitedExecutive office400 - 837 West Hastings Street Vancouver, BC V6C 3N6, Canada Tel: 1.604.283.1722 Subsidiary office AustraliaC/- JM Corporate ServicesLevel 6, 350 Collins Street Melbourne, VIC, Australia 3000Forward-Looking StatementsCertain information regarding Kincora contained herein may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements may include estimates, plans, expectations, opinions, forecasts, projections, guidance or other statements that are not statements of fact. Although Kincora believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Kincora cautions that actual performance will be affected by a number of factors, most of which are beyond its control, and that future events and results may vary substantially from what Kincora currently foresees. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration results, continued availability of capital and financing and general economic, market or business conditions. The forward-looking statements are expressly qualified in their entirety by this cautionary statement. The information contained herein is stated as of the current date and is subject to change after that date. Kincora does not assume the obligation to revise or update these forward-looking statements, except as may be required under applicable securities laws.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) or the Australian Securities Exchange accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/267334 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHANGHAI, Sep 22, 2025 - (ACN Newswire via SeaPRwire.com) – Gamehaus Holdings Inc. (NASDAQ: GMHS) today announced Gamehaus 2.0, a global, lifecycle-integrated publishing model designed to make hit creation more predictable. The strategy pairs an outside-in approach—integrating the best-fit creative teams at each stage of games’ lifecycle—with an inside-out engine, the GBS (Gamehaus Business System), which standardizes and scales enablement across discovery, development, launch and live operations.The Industry’s Pain Point: “Unpredictable Hits,” and Traditional Publishing that Bets on Luck.It is often difficult for the game industry to predict hot items. For game publishers, the conventional approach typically follows a linear “horizontal division of labor” where development, publishing and operation function merely as sequential handoffs, resulting in data gaps and inefficiencies. Publishers also bet on the opportunity to create hit titles.As the intermediary connecting upstream developers with downstream players, publishers are inherently positioned to act as “coordinators.” The difficulty in predicting hit titles may be solved by breaking data silos across all stages, efficiently integrating supply chain resources throughout the game lifecycle and building a robust empowerment platform. Gamehaus fully understands this challenge, with its forward-looking strategic upgrade underway to redefine the paradigm of game publishing.A Distilled Mission and Vision—A Timely Choice Born to Solve the Pain Point.Recently, Gamehaus officially unveiled its newly refined corporate mission and vision, of which the core essence organically and deeply aligns with the strategic direction of “Gamehaus 2.0.”Gamehaus' new mission – Bridge global game creators and players, making every crafted game spark passion in billion – reflects the Company’ s central identity: connecting the craftsmanship of creators on one side with the passion and expectations of players on the other. Gamehaus discovers high-quality ideas globally, empower small and midsize teams to bridge resource gaps, and—through professional global publishing and precision live operations—helps titles overcome geographic barriers and reach the right audiences, so that every crafted game can be seen and loved.Gamehaus’s new vision – Be the go-to partner for creative studios, launching breakout hits that redefine play – emphasizes the Company's commitment to lead the way and be the pivotal partner for creative studios. Through supply-chain integration and the GBS platform, Gamehaus will create a magnet for global ideas and talent, becoming the preferred partner across the entire journey from incubation to breakout. Gamehaus will consistently deliver works that are foundationally innovative –in mechanics, presentation, narrative, technology, or business model—and that, powered by strong organic spread and word of mouth, reset player expectations.Integrating a Global Creative Supply Chain Across the Full Lifecycle—Operationalizing Three Stages of Publishing.Unlike the conventional linear model, the Company, under its upgraded Gamehaus 2.0 business model, is embedded throughout the entire game lifecycle, achieving end-to-end oversight of ideas, products, commercialization and asset value. For example, during the upstream game concept and development stage, the Company leads product planning and process management, controlling the source and core value of the supply chain. In the midstream publishing and promotion stage, it manages channels and user acquisition, acting as the organizer of traffic. Downstream operation and value expansion focus on user services and asset enhancement, extending through monetization.Today, Gamehaus is building a global, multi-tiered and creative supply chain network through partnership, investment, customized development, mergers and acquisitions. Under the 2.0 model, the Company can flexibly deploy prominent development teams and creative resources to match different business scenarios and stages, maximizing commercial outcomes.In the zero-to-one creative validation stage (the earliest phase of turning an idea into a workable prototype), Gamehaus plays a role akin to a Hollywood producer, “sourcing” creative options globally, allowing small teams to focus primarily on validating zero-to-one creative prototypes through customized approaches. In the one-to-10 product crafting stage (scaling validated prototypes into polished, premium products), validated prototypes are handed over to more efficient and industrialized studios for premium and scalable development. In the 10-to-100 global expansion stage (growing proven products into large-scale, international franchises), Gamehaus acquires mature products and integrates them into the GBS platform for unified user acquisition, branding, community management, compliance and long-term operations. By redefining these three critical stages, Gamehaus is reshaping and integrating the global casual mobile game supply chains.Building the GBS Platform and a “Three-Capability Flywheel” to Become the Partner of Choice for Creative Teams Worldwide.Besides external global resource integration, Gamehaus has built the GBS (Gamehaus Business System) as an internal service platform, providing one-stop comprehensive services to global creative teams and positioning itself as their go-to partner. The GBS platform encompasses three modules, creating a flywheel of “discovery, empowerment and amplification.” These three factors reinforce one another, creating a flywheel effect.In the stage of value discovery, Gamehaus acts as the industry’s “talent scout and connoisseur,” analyzing global markets by integrating data from sources such as Sensor Tower, Steam wish lists, and TikTok trends to identify rising categories, potential hot items and outstanding development teams. This discovery capability has become a core competitive advantage of the Company.In terms of ecological empowerment, Gamehaus provides more than simple financial support -- it also offers comprehensive management capability for creative partners, allowing developers to focus more on creativity and development. With one click on the GBS platform, even teams of fewer than ten people can secure support comparable to major game studios.Furthermore, leveraging a mature publishing system, industrialized content pipelines and China’s unique development efficiency, Gamehaus can scale, globalize and extend the lifecycle of validated titles. This value-realization capability is like alchemy, turning a “raw creative stone” into a “commercial diamond”, rapidly pushing validated titles to global markets and enhancing their full lifecycle value.Advancing 2.0 Execution and Accelerating Comprehensive AI IntegrationThis year, the narrative of “European creativity + Chinese speed” is taking shape. Gamehaus has collaborated with Brainamic (Germany) and Beek (Türkiye), where relevant creative projects have entered the stage of demo verification and achieved positive progress. Gamehaus is actively seeking to establish long-term partnerships with more creative studios, ensuring a robust pipeline that delivers high-quality prototypes ready for polishing and publishing.Meanwhile, Gamehaus is rapidly advancing AI integration. The company is driving a comprehensive fusion of an AI-centric technology engine with the GBS platform—building an accelerated “AI + GBS” enablement system. In this system, AI technologies including AIGC, AI Agents and data intelligence are fully embedded into the discovery, empowerment and amplification system of GBS, building a digital infrastructure for the game industry and closing the loop of “discovery, empowerment and amplification”.Gamehaus 2.0 is not only about redefining publishing; it aspires to reshape the global standards of creative game production. Looking ahead, Gamehaus will ground its efforts in a reusable methodology and structured knowledge base, so that each success in the global casual-mobile publishing value chain becomes traceable and teachable—steadily turning vision into reality with disciplined execution and refined craft.About GamehausGamehaus Holdings Inc. is a technology-driven global mobile game publisher dedicated to bridging creative studios and players worldwide. With a portfolio spanning mid-core and casual games, Gamehaus delivers full-stack publishing support across market insights, user growth, live-ops, data analytics and monetization optimization. With a vision to be the go-to partner for creative teams, the company specializes in combining global publishing reach with AI- and data-powered solutions to help partners build lasting success. For more information, please visit https://ir.gamehaus.com.Forward-Looking StatementsCertain statements in this announcement are forward-looking statements, including, but not limited to, the Company’s business plan and outlook. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may”, or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results due to various risks and uncertainties, including but not limited to those described under the ‘Risk Factors’ section in the Company’s most recent filings with the U.S. Securities and Exchange Commission.Investor Relations ContactGamehaus Holdings Inc.Investor Relations TeamEmail: IR@Gamehaus.comThe Blueshirt GroupMr. Jack WangEmail: Gamehaus@TheBlueshirtGroup.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com